EP3439662
FLJÓTANDI SAMSETNINGAR AF (S)-N-(5-((R)-2-(2,5-DÍFLÚORFENÝL)-PÝRRÓLIDÍN-1-ÝL)-PÝRASÓLÓ[1,5-A]PÝRIMÍDÍN-3-ÝL)-3 -HÝDROXÝPÝRRÓLIDÍN-1-KARBOXAMÍÐ
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
4.4.2017EP published:
24.7.2024EP application number:
17718256.5
EP translation filed:
10.9.2024Grant published:
15.10.2024EPO information:
European Patent Register
Max expiry date:
3.4.2037Expiry date:
3.4.2026Next due date:
30.4.2026
Title in English:
LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDELanguage of the patent:
English
Timeline
Today
4.4.2017EP application
24.7.2024EP Publication
10.9.2024Translation submitted
15.10.2024Registration published
3.4.2026Expires
Owner
Name:
Loxo Oncology, Inc.Address:
281 Tresser Boulevard 9th Floor, Stamford, Connecticut 06901, US
Inventor
Name:
REYNOLDS, MarkAddress:
Stamford Connecticut 06901, US
Name:
SMITH, Steven A.Address:
Stamford Connecticut 06901, US
Agent
Name:
Novagraaf BrevetsAddress:
Bâtiment O2, 2 rue Sarah Bernhardt CS90017, FR
Priority
Number:
201662318041 PDate:
4.4.2016Country:
US
Number:
201662323452 PDate:
15.4.2016Country:
US
Number:
201662329561 PDate:
29.4.2016Country:
US
Classification
Categories:
A61K 31/519, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 9
Paid: 14.3.2025
Expires: 3.4.2026
Payer: Árnason Faktor ehf.